secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001683168-22-007719
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon reports Q2 net loss $3.8M; terminates COVID trial, launches Australia sub
--------------------------------------------------------------------------------

- Cash balance $19.6M as of Sep 30, 2022; operating expenses $3.67M, up 71% YoY.
- Terminated US COVID trial due to scarce ICU patients; expects $5M savings over 12 months.
- Launched wholly owned Australian subsidiary in Oct 2022 to conduct oncology studies.
- Dissolved Exosome Sciences, Inc., recording $142K non-cash charge in Q2.
- Raised ~$8.9M net proceeds from ATM stock sales in H1 fiscal 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/0001683168-22-007719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-007719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer